A Single Dose, 4-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effect of JNJ-42847922 on Polysomnography (PSG) Measures in Subjects With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants

Trial Profile

A Single Dose, 4-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effect of JNJ-42847922 on Polysomnography (PSG) Measures in Subjects With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Seltorexant (Primary)
  • Indications Insomnia; Major depressive disorder
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 20 Sep 2016 Primary endpoint has been met. (Latency to Persistent Sleep (LPS) on Day 1)
    • 20 Sep 2016 Results presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
    • 16 Jun 2015 Data from this study were presented by Janssen at the 29th annual meeting of the Associated Professional Sleep Societies, according to a Minerva Neurosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top